Company: PCRX
Filing Date: 2025-02-27
Form Type: 10-K
Source: 0001396814-25-000041
Chunk: 295

Company: Pacira BioSciences, Inc.
Filing Date: 2025-02-27
Form: 10-K
Item: Item 8
Chunk 295
---
 (7,945)Depreciation of fixed assets and amortization of intangible assets78,785 75,574 91,501 Amortization of debt issuance costs3,130 2,996 4,400 Amortization of debt discount92 752 2,807 (Gain) loss on early extinguishment of debt(7,518)16,926 — Stock-based compensation51,171 47,895 48,092 Changes in contingent consideration(4,457)(3,424)(29,476)Impairment of indefinite-lived intangible asset— — 26,134 Impairment of investment— — 10,000 Other net losses236 2,137 285 Changes in operating assets and liabilities:   Accounts receivable, net(7,748)(7,159)(2,079)Inventories, net(20,929)(8,290)2,486 Prepaid expenses and other assets(7,360)(9,639)(2,699)Accounts payable3,084 916 6,272 Accrued expenses and income taxes payable11,720 (22,039)(19,857)Other liabilities2,714 434 (556)Net cash provided by operating activities189,389 154,649 145,274 Investing activities:   Purchases of fixed assets(10,636)(15,161)(30,076)Purchases of available-for-sale investments(252,212)(137,608)(387,685)Sales of available-for-sale investments179,572 237,068 237,576 Payment of contingent consideration— — (32,000)Purchases of debt and equity investments— (6,758)(13,000)Net cash (used in) provided by investing activities(83,276)77,541 (225,185)Financing activities:   Proceeds from exercises of stock options— 1,939 24,387 Proceeds from shares issued under employee stock purchase plan2,298 2,811 2,954 Payment of employee withholding taxes on restricted stock unit vests(491)(106)— Purchase of treasury stock(25,000)— — Proceeds from 2029 convertible senior notes287,500 — — Proceeds from Term loan A facility— 149,550 — Repayment of